Thomas Campbell is an Infectious Disease physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 29 Nov 2012.
Clinical trials
- Plant-Based Nutrition for Breast or Endometrial Cancer
Sponsor: University of Rochester
- Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health
Sponsor: University of Rochester
- Effects of a Plant-Based Diet on Insulin Requirements and Obesity Markers in Obese Adults With T2DM
Sponsor: University of Rochester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
51.6%Protease Inhibitor22.2%Prezcobix29%Atazanavir Sulfate19%Ritonavir19%Symtuza19%Darunavir14%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor9.3%Tivicay66%Isentress34%Part D<11 patients+ 6 more classes in this area
Nervous system
12.7%SSRI3.4%Citalopram Hbr100%Part D<11 patientsBenzodiazepine3.2%Diazepam100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
9.3%Statin6.1%Pravastatin Sodium52%Atorvastatin Calcium48%Part D<11 patientsOther lipid modifying agents3.2%Vascepa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
18 NIH research awards on record, funded 1992–2024 per NIH RePORTER. The latest:
- Training Program for Antiretroviral Discovery, Evaluation and Application Research (ADEAR)
University of Colorado Denver
FY2024$201,858T32AI150547 - Training Program for Antiretroviral Discovery, Evaluation and Application Research (ADEAR)
University of Colorado Denver
FY2023$152,930T32AI150547 - Training Program for Antiretroviral Discovery, Evaluation and Application Research (ADEAR)
University of Colorado Denver
FY2022$234,484T32AI150547
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”